| 1 Leaving the study early: 1. Any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 short term |
1 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.15, 6.55] |
| 2 Global state: 1. Change over time ‐ no better or deterioration (ITT) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 short term |
1 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
0.67 [0.21, 2.08] |
| 3 Adverse events: Movement disorders |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 use of antiparkinsonian drugs ‐ short term |
1 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
0.53 [0.31, 0.89] |
| 4 Other adverse events: 1. Arousal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 need of additional benzodiazepines ‐ short term |
1 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
0.5 [0.24, 1.03] |
| 5 Other adverse events: 2. lab data |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 slight T‐wave changes on EKG ‐ short term |
1 |
50 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.15, 6.55] |
